DEXCOM INC (DC4.DE) Stock Price, Forecast & Analysis
Europe - Frankfurt Stock Exchange - FRA:DC4 - US2521311074 - Common Stock
DC4.DE Key Statistics, Chart & Performance
The current stock price of DC4.DE is 56.56 EUR. In the past month the price increased by 8.77%. In the past year, price decreased by -27.59%.
DC4.DE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1MDT.MI | MEDTRONIC PLC | 17.59 | 107.77B | ||
| 2M6.DE | MEDTRONIC PLC | 17.36 | 106.36B | ||
| SHL.DE | SIEMENS HEALTHINEERS AG | 18.62 | 50.20B | ||
| PHI1.DE | KONINKLIJKE PHILIPS NV | 15.41 | 21.95B | ||
| 1PHIA.MI | KONINKLIJKE PHILIPS NV | 15.38 | 21.92B | ||
| PHIA.AS | KONINKLIJKE PHILIPS NV | 15.36 | 21.90B | ||
| BIM.PA | BIOMERIEUX | 28.5 | 13.02B | ||
| OBCK.DE | OTTOBOCK SE & CO KGAA | 137.87 | 4.15B | ||
| DIA.MI | DIASORIN SPA | 20.13 | 3.73B | ||
| AFX.DE | CARL ZEISS MEDITEC AG - BR | 25.03 | 3.60B | ||
| DRW3.DE | DRAEGERWERK AG - PREF | 10.6 | 1.28B | ||
| ELN.MI | EL.EN. SPA | 21.7 | 1.12B |
Related stock screener links
About DC4.DE
Company Profile
DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. The company is headquartered in San Diego, California and currently employs 10,300 full-time employees. The company went IPO on 2005-04-14. The firm is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6, Dexcom G7, Stelo, Dexcom Share, and Dexcom ONE. The firm enables people to take control of health through innovative biosensing technology. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes.
Company Info
DEXCOM INC
6340 Sequence Drive
San Diego CALIFORNIA US
Employees: 10250
Phone: 18582000200
DEXCOM INC / DC4.DE FAQ
What does DEXCOM INC do?
DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. The company is headquartered in San Diego, California and currently employs 10,300 full-time employees. The company went IPO on 2005-04-14. The firm is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6, Dexcom G7, Stelo, Dexcom Share, and Dexcom ONE. The firm enables people to take control of health through innovative biosensing technology. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes.
Can you provide the latest stock price for DEXCOM INC?
The current stock price of DC4.DE is 56.56 EUR. The price decreased by -1.69% in the last trading session.
What is the dividend status of DEXCOM INC?
DC4.DE does not pay a dividend.
How is the ChartMill rating for DEXCOM INC?
DC4.DE has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
How is the valuation of DEXCOM INC (DC4.DE) based on its PE ratio?
The PE ratio for DEXCOM INC (DC4.DE) is 35.8. This is based on the reported non-GAAP earnings per share of 1.58 and the current share price of 56.56 EUR.
What is the market capitalization of DC4 stock?
DEXCOM INC (DC4.DE) has a market capitalization of 22.06B EUR. This makes DC4.DE a Large Cap stock.
What is the ownership structure of DEXCOM INC (DC4.DE)?
You can find the ownership structure of DEXCOM INC (DC4.DE) on the Ownership tab.
DC4.DE Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to DC4.DE. When comparing the yearly performance of all stocks, DC4.DE is a bad performer in the overall market: 87.8% of all stocks are doing better.
DC4.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to DC4.DE. DC4.DE scores excellent on profitability, but there are some minor concerns on its financial health.
DC4.DE Financial Highlights
Over the last trailing twelve months DC4.DE reported a non-GAAP Earnings per Share(EPS) of 1.58. The EPS increased by 9.41% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 15.96% | ||
| ROA | 9.61% | ||
| ROE | 26.44% | ||
| Debt/Equity | 0.47 |
DC4.DE Forecast & Estimates
37 analysts have analysed DC4.DE and the average price target is 74.43 EUR. This implies a price increase of 31.6% is expected in the next year compared to the current price of 56.56.
For the next year, analysts expect an EPS growth of 27.26% and a revenue growth 15.38% for DC4.DE